Predict your next investment

Incubator/Accelerator
bioinnovation.co

See what CB Insights has to offer

Investments

16

Portfolio Exits

6

Funds

1

About BioInnovation Capital

BioInnovation Capital invests in promising life science companies.

BioInnovation Capital Headquarter Location

1 Broadway 14th Floor

Cambridge, Massachusetts, 02142,

United States

617-276-5578

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BioInnovation Capital News

Pandion Therapeutics Closes $80M Series B Financing

Apr 1, 2020

Pandion Therapeutics, Inc. , a Cambridge, MA-based clinical-stage, biotechnology company developing modular protein therapeutics for autoimmune disease, closed an $80m Series B financing. The round was led by Access Biotechnology and Boxer Capital with participation from RA Capital and OrbiMed and existing investors Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, JDRF T1D Fund and BioInnovation Capital. In conjunction with the funding, Dan Becker, M.D., Ph.D, Principal, Access Biotechnology and Christopher Fuglesang, Ph.D, J.D., Co-Founder and Managing Director of Boxer Capital will be joining the Pandion Board of Directors. The company intends to use the funds for the continued development of multiple product candidates in its pipeline, including lead clinical-stage program, PT101, a novel interleukin 2 (IL-2) mutein Fc fusion protein, which is currently in Phase 1 clinical development; bringing a second program into the clinic; broadening its modular drug design platform, and for expansion of the team and infrastructure. Led by Rahul Kakkar, M.D., Chief Executive Officer, Pandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. The company is advancing its lead drug candidate, PT101, an IL-2 mutein Fc fusion protein that preferentially expands regulatory T cells, as well as a pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas. FinSMEs 01/04/2020

BioInnovation Capital Investments

16 Investments

BioInnovation Capital has made 16 investments. Their latest investment was in Pandion Therapeutics as part of their Series B on April 4, 2020.

CBI Logo

BioInnovation Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/1/2020

Series B

Pandion Therapeutics

$80M

No

10

11/7/2019

Series A

Arkuda Therapeutics

$44M

Yes

3

9/18/2019

Convertible Note

Totient

Yes

6

6/28/2019

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/13/2019

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/1/2020

11/7/2019

9/18/2019

6/28/2019

6/13/2019

Round

Series B

Series A

Convertible Note

Seed VC

Series A - II

Company

Pandion Therapeutics

Arkuda Therapeutics

Totient

Subscribe to see more

Subscribe to see more

Amount

$80M

$44M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

3

6

10

10

BioInnovation Capital Portfolio Exits

6 Portfolio Exits

BioInnovation Capital has 6 portfolio exits. Their latest portfolio exit was Comet Therapeutics on August 31, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/31/2021

Acquired

VectivBio

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

8/31/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

VectivBio

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

BioInnovation Capital Fund History

1 Fund History

BioInnovation Capital has 1 fund, including BioInnovation Capital I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/15/2017

BioInnovation Capital I

Early-Stage Venture Capital

$65.63M

3

Closing Date

2/15/2017

Fund

BioInnovation Capital I

Fund Type

Early-Stage Venture Capital

Status

Amount

$65.63M

Sources

3

BioInnovation Capital Team

3 Team Members

BioInnovation Capital has 3 team members, including current Chief Financial Officer, Susie Harborth.

Name

Work History

Title

Status

Susie Harborth

Chief Financial Officer

Current

Eric W. Linsley

Managing General Partner

Current

Peter Parker

Ampersand Capital Partners

Managing General Partner

Current

Name

Susie Harborth

Eric W. Linsley

Peter Parker

Work History

Ampersand Capital Partners

Title

Chief Financial Officer

Managing General Partner

Managing General Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.